Absence of association between Pfnfs1 mutation and in vitro susceptibility to lumefantrine in Plasmodium falciparum

Int J Parasitol Drugs Drug Resist. 2024 Apr:24:100532. doi: 10.1016/j.ijpddr.2024.100532. Epub 2024 Mar 19.

Abstract

Artemether-lumefantrine (AL) is the most widely used antimalarial drug for treating uncomplicated falciparum malaria. This study evaluated whether the K65Q mutation in the Plasmodium falciparum cysteine desulfurase IscS (Pfnfs1) gene was associated with alternated susceptibility to lumefantrine using clinical parasite samples from Ghana and the China-Myanmar border area. Parasite isolates from the China-Myanmar border had significantly higher IC50 values to lumefantrine than parasites from Ghana. In addition, the K65 allele was significantly more prevalent in the Ghanaian parasites (34.5%) than in the China-Myanmar border samples (6.8%). However, no difference was observed in the lumefantrine IC50 value between the Pfnfs1 reference K65 allele and the non reference 65Q allele in parasites from the two regions. These data suggest that the Pfnfs1 K65Q mutation may not be a reliable marker for reduced susceptibility to lumefantrine.

Keywords: In vitro susceptibility; Lumefantrine; Pfnfs1 gene; Plasmodium falciparum.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Artemether / therapeutic use
  • Artemether, Lumefantrine Drug Combination / therapeutic use
  • Artemisinins* / pharmacology
  • Artemisinins* / therapeutic use
  • Drug Resistance / genetics
  • Ethanolamines / pharmacology
  • Ethanolamines / therapeutic use
  • Ghana
  • Humans
  • Lumefantrine / pharmacology
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / parasitology
  • Mutation
  • Plasmodium falciparum

Substances

  • Lumefantrine
  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Artemether
  • Ethanolamines